Longterm Clinical Recovery in Parkinsonian Monkey Recipients of Ctla4-Ig Transgenic Porcine Neural Precursors

badin, Aron R.; Padoan, A.; Vadori, Marta; Boldrin, M; Cavicchioli, Lionel; Benedictis, Giulia Maria De; Fante, F; Seveso, M; Sgarabotto, Dino; Jan, C.; Daguin, Véronique; Naveilhan, Philippe; Neveu, Isabelle; Jp, Soulillou; Vanhove, Bernard; Plat, Martine; Botté, Françoise; Eric, V.; Denaro, Luca; Manara, Renzo; Zampieri, Paolo; D’Avella, Domenico; Rubello, Domenico; Ancona, Ermanno; Hantraye, Philippe; Cozzi, E.

doi:10.1097/00007890-201007272-00090

Cited by 11 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As discussed elsewhere in this issue, approaches such as stem cell therapy or bioengineered devices are not sufficiently successful yet to consider as an alternative to allotransplantation. Xenotransplantation is much closer to meaningful clinical trials, and these could be initiated either through cellular xenotransplantation [15,30,31] or as a ‘bridge’ to liver [32] or heart [33] allotransplantation.…”

Section: Discussionmentioning

confidence: 99%

“…Although there is only one significant study, the evidence is that porcine dopamine-producing cells can reverse the clinical features of a Parkinson-like disease in monkeys [31]. …”

Section: Potential Of Xenotransplantationmentioning

confidence: 99%

“…Microencapsulated pancreatic islets = 804 days (with re-Tx), 250 days (without re-Tx) (Sun et al [35]) (wild-type [WT] pigs); Neuronal cells = >521 days (Badin et al [31]) (CTLA4-Ig transgenic pigs); pancreatic islets = 396 days (van der Windt et al [36]) (hCD46 pigs); cornea (full thickness) = >933 days (Choi et al [37]) (WT pigs); hepatocytes = 243 days (with re-Tx), 80 days (without re-Tx) (Nagata et al [38]) (WT pigs); heterotopic heart = >500 days (Mohiuddin et al [18]) (GTKO/hCD46/hTBM pigs); kidney = >240 days (Tector AJ, personal communication) (GTKO/hCD55 pigs); orthotopic heart = 57 days (McGregor et al [19]) (GTKO/hCD55 pigs); liver = 9 days (Kim K et al [28]) (hCD55 pigs); lung = 5 days (Cantu et al [29]) (vWF-deficient pigs). Figure modified from Ekser B et al [15].…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

The need for xenotransplantation as a source of organs and cells for clinical transplantation

Ekser

Cooper

Tector

2015

International Journal of Surgery

View full text Add to dashboard Cite

The limited availability of deceased human organs and cells for the purposes of clinical transplantation remains critical worldwide. Despite the increasing utilization of ‘high-risk’, ‘marginal’, or ‘extended criteria’ deceased donors, in the U.S. each day 30 patients either die or are removed from the waiting list because they become too sick to undergo organ transplantation. In certain other countries, where there is cultural resistance to deceased donation, e.g., Japan, the increased utilization of living donors, e.g., of a single kidney or partial liver, only very partially addresses the organ shortage. For transplants of tissues and cells, e.g., pancreatic islet transplantation for patients with diabetes, and corneal transplantation for patients with corneal blindness (whose numbers worldwide are potentially in the millions), allotransplantation will never prove a sufficient source. There is an urgent need for an alternative source of organs and cells. The pig could prove to be a satisfactory source, and clinical xenotransplantation using pig organs or cells, particularly with the advantages provided by genetic engineering to provide resistance to the human immune response, may resolve the organ shortage. The physiologic compatibilities and incompatibilities of the pig and the human are briefly reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although there is only one significant study, the evidence is that porcine dopamine-producing cells can reverse the clinical features of a Parkinson-like disease in monkeys [31]. …”

Section: Potential Of Xenotransplantationmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

The need for xenotransplantation as a source of organs and cells for clinical transplantation

Ekser

Cooper

Tector

2015

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…The most significant of these are human anti-pig antibodies that target galac-Open Journal of Organ Transplant Surgery tose-α 1, 3-galactose antigens expressed on porcine organs [27]. Porcine organs that are knockouts for the α 1, 3-galactosyltransferase gene have shown promise in preventing early rejection, however, other antibodies and immune cells can still induce rejection [28]. Currently, xenotransplantation of islet or neuronal cells shows more promise than that of organ xenotransplantation.…”

Section: Xenotransplantationmentioning

confidence: 99%

“…Pig islet cells have been shown to continue to function in non-human primates for more than a year [29] [30]. Success has also been demonstrated in xenotransplantation of dopamine-producing cells from pigs to monkeys with a Parkinson's-like condition [28] [29]. Furthermore, cardiac graft survival in pig-to-non-human primates has shown survival of up to 8 months [29] [30].…”

Section: Xenotransplantationmentioning

confidence: 99%

New Frontiers in Transplantation and Stem Cell Technology: A Brief Synopsis

Javadi¹,

Brooks²,

Obi-Umahi³

et al. 2018

OJOTS

View full text Add to dashboard Cite

Since the first kidney transplant was performed in 1954 immense progress has been made in the world of transplantation. Modern immunosuppressive regimens have led to increasing graft and patient survival after solid organ transplantation. Furthermore, these advances have opened the door to new fields of transplantation such as composite tissue allotransplantation. These developments have made possible numerous types of transplantation including, but not limited to face, penile, and uterine transplantation. Moreover, innovations in genetic engineering and stem cell technology have contributed to rapid developments in the fields of xenotransplantation and the engineering of functional organs from induced pluripotent stem cells. As the prevalence of chronic diseases rises, so too will the necessity for organ transplantation. Thus, the transplant innovations of the modern era need to be expanded upon so as to continue to discover new ways to address organ shortages and the complications of transplantation.

show abstract